^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Kinase inhibitor

    Related drugs:
    2d
    RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=159, Completed, EIP Pharma Inc | Trial primary completion date: Oct 2024 --> May 2025
    Trial primary completion date
    5d
    CDDO-Me alleviates doxorubicin/lapatinib-induced cardiotoxicity by activating the NRF2/GPX4 axis to inhibit oxidative stress and ferroptosis. (PubMed, Free Radic Biol Med)
    Furthermore, CDDO-Me did not compromise the antitumor efficacy of DOX/LAP in breast cancer cells. CDDO-Me protects against DOX/LAP-induced cardiotoxicity by stabilizing GPX4 and inhibiting ferroptosis, offering a promising therapeutic strategy that preserves cardiac function without interfering with chemotherapy.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    lapatinib • doxorubicin hydrochloride
    5d
    DO2.22.01: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours (clinicaltrials.gov)
    P1, N=55, Recruiting, DeuterOncology | N=25 --> 55 | Trial completion date: Dec 2026 --> Sep 2028 | Trial primary completion date: Dec 2025 --> Sep 2027 | Active, not recruiting --> Recruiting
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET exon 14 mutation
    |
    DO-2
    7d
    A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies (clinicaltrials.gov)
    P2, N=25, Completed, EIP Pharma Inc | Active, not recruiting --> Completed
    Trial completion
    8d
    Discovery of New CDDO-Imidazole Derivatives as Potential Antitumor Agents. (PubMed, ChemMedChem)
    Notably, 8 exhibited significant antitumor efficacy comparable to CDDO-Me (bardoxolone methyl), which had entered clinical trials. Taken together, 8 represents a promising candidate for the treatment of cancer and merits further study.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
    12d
    Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms (clinicaltrials.gov)
    P1/2, N=160, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Vonjo (pacritinib)
    19d
    LIBRETTO-531: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (clinicaltrials.gov)
    P3, N=291, Active, not recruiting, Loxo Oncology, Inc. | Trial completion date: Feb 2026 --> Nov 2027
    Trial completion date
    |
    RET (Ret Proto-Oncogene)
    |
    RET mutation • RET positive
    |
    Cabometyx (cabozantinib tablet) • Retevmo (selpercatinib) • Caprelsa (vandetanib)
    21d
    STELLA: A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=442, Recruiting, Artios Pharma Ltd | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD • BRCA mutation
    |
    gemcitabine • irinotecan • alnodesertib (ART0380)
    22d
    Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=120 --> 37 | Trial primary completion date: Aug 2026 --> Dec 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    berzosertib (M6620) • Zepzelca (lurbinectedin)
    27d
    SEEK: Safety and Efficacy of Atezolizumab-Bevacizumab Versus Tyrosin Kinase Inhibitors in Patients With Liver Cirrhosis (clinicaltrials.gov)
    P=N/A, N=38, Completed, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Active, not recruiting --> Completed | N=741 --> 38
    Trial completion • Enrollment change
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    1m
    ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (clinicaltrials.gov)
    P=N/A, N=30, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial • IO biomarker
    |
    ABL2 (ABL Proto-Oncogene 2, Non-Receptor Tyrosine Kinase)
    |
    Venclexta (venetoclax) • cytarabine • Jakafi (ruxolitinib) • cyclophosphamide • Blincyto (blinatumomab) • Nailike (olverembatinib) • fludarabine IV
    3ms
    OMX-0407-101: A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically (clinicaltrials.gov)
    P1/2, N=188, Active, not recruiting, iOmx Therapeutics AG | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Jun 2026
    Enrollment closed • Trial primary completion date
    |
    OMX-0407